VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity
about
Computational systems analysis of dopamine metabolismVMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuseSynaptic vesicle trafficking and Parkinson's diseaseVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryTrafficking of vesicular neurotransmitter transportersVesicular monoamine transporter 2: role as a novel target for drug developmentElimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 geneGenetically engineered mouse models of Parkinson's diseaseParkinson's disease: animal models and dopaminergic cell vulnerabilityLobelane decreases methamphetamine self-administration in ratsDefunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporterExperimenting with spirituality: analyzing The God Gene in a nonmajors laboratory courseIdentification of a gastrin response element in the vesicular monoamine transporter type 2 promoter and requirement of 20 S proteasome subunits for transcriptional activityVesicular integrity in Parkinson's diseaseInvolvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neuronsFuzzy Decision Making Approach to Identify Optimum Enzyme Targets and Drug Dosage for Remedying Presynaptic Dopamine DeficiencyAltered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptorDisease-toxicant interactions in Parkinson's disease neuropathologyChronic Toxoplasma gondii in Nurr1-null heterozygous mice exacerbates elevated open field activityThe Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Deletion of Go2alpha abolishes cocaine-induced behavioral sensitization by disturbing the striatal dopamine systemBehavioral genetic contributions to the study of addiction-related amphetamine effects.The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.NrCAM-regulating neural systems and addiction-related behaviors.Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein deltaLobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.Vmat2 heterozygous mutant mice display a depressive-like phenotype.Venous endothelin guides sympathetic innervation of the developing mouse heart.The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.Measurement of anxiety in transgenic mice.Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosisCould a common biochemical mechanism underlie addictions?High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivoDose-dependent attenuation of heroin self-administration with lobeline.Expression of neurotransmitter transporters for structural and biochemical studiesPreparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2.Suppression of glia maturation factor expression prevents 1-methyl-4-phenylpyridinium (MPP⁺)-induced loss of mesencephalic dopaminergic neurons
P2860
Q21144295-7A8AC4E1-5DD4-4FFB-BB1A-E47513C64C5EQ22242306-8BC962E1-6E03-4010-9B37-DBB9AD52FDAEQ24302024-A5492F67-0337-4088-AD85-EC2CF3068188Q24601233-5E199ECC-C8B3-485E-A397-21BAC6466869Q24619054-283ECAAC-1B26-458B-B208-5EBCF2ABA60BQ24647764-1D88ACA1-F0DA-4401-9341-CAE8C6317F83Q24671498-E2FDE16A-0940-444D-831D-F5AEB153AAF5Q26852964-E2CCCC8E-30DC-4369-BCF3-F23E2B82D54FQ28080503-D393B7A7-A291-4D13-BA53-BE81B0BAF533Q28235359-5390B3F9-394B-466F-91C9-6169E1EA6D22Q28267727-7166F434-1979-4D09-9520-3D5E87BDE9BAQ28271336-BE265098-0FFA-4257-84C8-0A2C2390536FQ28298413-5871DE88-ED05-4694-AD23-21240860712EQ28385737-5CF03893-FE33-45D8-A371-C6156295FB65Q28512859-9041D9A0-A911-47DF-AD65-C269A930AF7BQ28554723-AC4DD5B9-7391-4812-A24F-D01C322DC6CCQ28588013-C27DD1E6-9B43-4149-B295-5D6510873DE5Q29248297-0D1DE291-6480-4676-A576-278AFFD4A9B6Q30413968-BA902801-49AD-48C8-96F3-DB485A6270ADQ30430534-7CA2CC68-CCCC-4C13-8E56-39F994C96652Q30483512-7F766438-464A-447D-837B-86B411D7C871Q30494693-F258C972-A488-416C-8C9E-1B69203E1A52Q30497495-F785EDE3-0619-4069-832C-80238A680961Q30525650-B5DDC25A-A03F-4857-8429-0924C56F1061Q30530645-1D4FD095-510B-4ABC-AF07-F4CBBBA7B64BQ33613631-C625D4DD-56BE-4D86-9956-934C92EEC4F0Q33724885-6DF3D214-18A0-4616-BE2A-661BA6402E5EQ33738102-5CCCFF1F-56A9-48A7-814B-BCE3C161B670Q33793549-3CB5935C-4E59-4BA8-A3CA-53BD853F3F3EQ33839833-796803D5-ADEC-4EE6-A0DF-E94282867153Q33854736-D2A45CEF-2472-4C32-87B9-D0963C9819D4Q33862518-1BA1D85E-D291-4EC3-9F4B-182E128918FEQ33862898-B660FB90-DA37-493C-996C-C09350DBC1ECQ33894614-D2E08D89-4F76-4C3F-9E5A-4C2DB1E3E11BQ33919434-8880F012-A49C-476C-94A8-B77BF29EF18CQ33919548-E20E8273-C8F5-4EF8-80E1-E211B2F96B87Q33958021-B32E7E58-AA22-4A50-9520-51B3762FF17FQ34032615-43F6CC73-BB71-4A3F-9585-BE86CFFACC69Q34042123-04F81B18-8CF0-4DFA-A263-BEE75B018227Q34183725-C9551739-E73E-4924-A46C-1BAA531772B7
P2860
VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity
description
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 1997
@ast
im September 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1997/09/02)
@sk
vědecký článek publikovaný v roce 1997
@cs
wetenschappelijk artikel (gepubliceerd op 1997/09/02)
@nl
наукова стаття, опублікована у вересні 1997
@uk
name
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@ast
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@en
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@nl
type
label
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@ast
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@en
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@nl
prefLabel
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@ast
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@en
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@nl
P2093
P2860
P3181
P356
P1476
VMAT2 knockout mice: heterozyg ...... on, and enhanced MPTP toxicity
@en
P2093
L. L. Miner
N. Takahashi
R. S. Revay
P2860
P304
P3181
P356
10.1073/PNAS.94.18.9938
P407
P577
1997-09-02T00:00:00Z